Glen Pierce

List of Publications by Year
in descending order

57 papers	7,705 citations	159358 30 h-index	155451 55 g-index
57 all docs	57 docs citations	57 times ranked	4691 citing authors

#	Article	IF	Citations
1	Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nature Medicine, 2006, 12, 342-347.	15.2	1,865
2	WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia, 2020, 26, 1-158.	1.0	915
3	CD8+ T-cell responses to adeno-associated virus capsid in humans. Nature Medicine, 2007, 13, 419-422.	15.2	629
4	AAV5â€“Factor VIII Gene Transfer in Severe Hemophilia A. New England Journal of Medicine, 2017, 377, 2519-2530.	13.9	529
5	Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood, 2014, 123, 317-325.	0.6	403
6	Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A. New England Journal of Medicine, 2020, 382, 29-40.	13.9	316
7	Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B. New England Journal of Medicine, 2013, 369, 2313-2323.	13.9	307
8	Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood, 2006, 108, 3321-3328.	0.6	295
9	Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood, 2012, 119, 3031-3037.	0.6	215
10	Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Critical Reviews in Biotechnology, 2015, 35, 235-254.	5.1	201
11	Evidence of Multiyear Factor IX Expression by AAV-Mediated Gene Transfer to Skeletal Muscle in an Individual with Severe Hemophilia B. Molecular Therapy, 2006, 14, 452-455.	3.7	196
12	Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood, 2012, 119, 666-672.	0.6	167
13	Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A. New England Journal of Medicine, 2022, 386, 1013-1025.	13.9	157
14	Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. Blood, 2012, 119, 3024-3030.	0.6	139
15	Biochemical and functional characterization of a recombinant monomeric factorÂVIIIâ€“Fc fusion protein. Journal of Thrombosis and Haemostasis, 2013, 11, 132-141.	1.9	116
16	Longâ€term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A. Haemophilia, 2016, 22, 72-80.	1.0	98
17	Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories. Haemophilia, 2014, 20, 294-300.	1.0	84
18	Novel approach to genetic analysis and results in 3000 hemophilia patients enrolled in the My Life, Our Future initiative. Blood Advances, 2017, 1, 824-834.	2.5	83

#	Article	IF	Citations
19	Core outcome set for gene therapy in haemophilia: Results of the core<scp>HEM</scp> multistakeholder project. Haemophilia, 2018, 24, e167-e172.	1.0	74
20	Novel Caprine Adeno-Associated Virus (AAV) Capsid (AAV-Go.1) Is Closely Related to the Primate AAV-5 and Has Unique Tropism and Neutralization Properties. Journal of Virology, 2005, 79, 15238-15245.	1.5	65
21	Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A. Haemophilia, 2021, 27, 947-956.	1.0	62
22	Recombinant factorÂVIII Fc fusion protein: extendedâ€interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. Journal of Thrombosis and Haemostasis, 2014, 12, 1788-1800.	1.9	56
23	Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thrombosis and Haemostasis, 2016, 116, 1-8.	1.8	52
24	The World Federation of Hemophilia Annual Global Survey 1999â€2018. Haemophilia, 2020, 26, 591-600.	1.0	50
25	Activity of transgene-produced B-domainâ€“deleted factor VIII in human plasma following AAV5 gene therapy. Blood, 2020, 136, 2524-2534.	0.6	48
26	Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A. Nature Medicine, 2022, 28, 789-797.	15.2	48
27	The Use of Purified Clotting Factor Concentrates in Hemophilia. JAMA - Journal of the American Medical Association, 1989, 261, 3434.	3.8	41
28	The use of purified clotting factor concentrates in hemophilia. Influence of viral safety, cost, and supply on therapy. JAMA - Journal of the American Medical Association, 1989, 261, 3434-3438.	3.8	40
29	Past, present and future of haemophilia gene therapy: From vectors and transgenes to known and unknown outcomes. Haemophilia, 2018, 24, 60-67.	1.0	35
30	Gene therapy: reality or myth for the global bleeding disorders community?. Haemophilia, 2002, 8, 261-267.	1.0	32
31	Firstâ€year results of an expanded humanitarian aid programme for haemophilia in resourceâ€constrained countries. Haemophilia, 2018, 24, 229-235.	1.0	32
32	The 1st <scp>WFH</scp> Gene Therapy Round Table: Understanding the landscape and challenges of gene therapy for haemophilia around the world. Haemophilia, 2019, 25, 189-194.	1.0	31
33	Validation of the manufacturing process used to produce longâ€acting recombinant factor <scp>IX</scp> Fc fusion protein. Haemophilia, 2014, 20, e327-35.	1.0	30
34	World Federation of Hemophilia Gene Therapy Registry. Haemophilia, 2020, 26, 563-564.	1.0	28
35	Uncertainty in an era of transformative therapy for haemophilia: Addressing the unknowns. Haemophilia, 2021, 27, 103-113.	1.0	28
36	Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2020, 18, 3074-3077.	1.9	24

#	Article	IF	Citations
37	Gene therapy to cure haemophilia: Is robust scientific inquiry the missing factor?. Haemophilia, 2020, 26, 931-933.	1.0	24
38	The COVIDâ€19 pandemic: New global challenges for the haemophilia community. Haemophilia, 2020, 26, 371-372.	1.0	21
39	Liver Gene Therapy: Reliable and Durable?. Molecular Therapy, 2019, 27, 1863-1864.	3.7	20
40	Establishing the appropriate primary endpoint in haemophilia gene therapy pivotal studies. Haemophilia, 2017, 23, 643-644.	1.0	18
41	Improving access to hemophilia care in sub-Saharan Africa by capacity building. Blood Advances, 2019, 3, 1-4.	2.5	17
42	Towards a global multidisciplinary consensus framework on haemophilia gene therapy: Report of the 2nd World Federation of Haemophilia Gene Therapy Round Table. Haemophilia, 2020, 26, 443-449.	1.0	15
43	Management of COVIDâ€19â€associated coagulopathy in persons with haemophilia. Haemophilia, 2021, 27, 41-48.	1.0	14
44	World bleeding disorders registry: The pilot study. Haemophilia, 2018, 24, e113-e116.	1.0	13
45	Eliminating Panglossian thinking in development of AAV therapeutics. Molecular Therapy, 2021, 29, 3325-3327.	3.7	12
46	Results of genetic analysis of 11â€‰341 participants enrolled in the My Life, Our Future hemophilia genotyping initiative in the United States. Journal of Thrombosis and Haemostasis, 2022, 20, 2022-2034.	1.9	10
47	Vaccination against COVIDâ€19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders. Haemophilia, 2021, 27, 515-518.	1.0	9
48	Gene Therapy for Hemophilia: Are Expectations Matching Reality?. Molecular Therapy, 2020, 28, 2097-2098.	3.7	8
49	Gene therapy for hemophilia: anticipating the unexpected. Blood Advances, 2020, 4, 3788-3788.	2.5	8
50	Reimbursing the value of gene therapy care in an era of uncertainty. Haemophilia, 2021, 27, 12-18.	1.0	7
51	Evaluation of the toxicology, pharmacokinetics, and local tolerance of recombinant factor IX Fc fusion protein in animals. Thrombosis Research, 2015, 136, 371-378.	0.8	6
52	A Cornucopia of Therapies under Study for Hemophilia. Molecular Therapy, 2017, 25, 2429-2430.	3.7	4
53	Evaluation of the toxicology and pharmacokinetics of recombinant factor VIII Fc fusion protein in animals. Thrombosis Research, 2015, 136, 1266-1272.	0.8	3
54	Impact of humanitarian aid linked prophylaxis in CÃ´te d'Ivoire (Ivory Coast). Haemophilia, 2021, 27, 9-11.	1.0	3

#	Article	IF	Citations
55	Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice. PLoS ONE, 2016, 11, e0148255.	1.1	2
56	Evaluation of the safety, pharmacokinetics, and efficacy of recombinant factor VIII fc fusion protein in Japanese subjects with severe haemophilia A: analysis from the A-LONG study. Japanese Journal of Thrombosis and Hemostasis, 2016, 27, 665-677.	0.1	0
57	Supporting patients with haemophilia in a world of crises: New role for the WFH and its partners. Haemophilia, 2022, 28, 521-522.	1.0	0